Barclays Lowers Stock Rating for Terns Pharmaceuticals Amid Merck Deal
Published on 3/30/2026
AI Summary
Summarized by AI from the source belowBarclays has downgraded the stock rating for Terns Pharmaceuticals, citing the recent deal with Merck. This change could influence investor sentiment and trading volumes for Terns Pharmaceuticals as the market reacts to the adjustment in outlook. The specifics of the rating change were not disclosed in the report. Analyst ratings can significantly impact stock prices and market positioning.
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
